Research
Hormonal
GLP-1-agonists significantly reduce the risk of cardiovascular endpoints in patients with overweight or obesity without diabetes, with a Number Needed to Treat (NNT) of 44.
GLP-1-agonists may be considered for reducing cardiovascular risk in non-diabetic patients with obesity.
StrongSupportsmedium confidence
Een recente meta-analyse liet bij patiënten met overgewicht of obesitas, maar zonder diabetes, bij gebruik van GLP-1-agonisten, een statistisch significante reductie van het risico op cardiovasculaire eindpunten zien, met een Number Needed to Treat (NNT) van 44.
Why this rating
The claim is based on a recent meta-analysis.
Source
GLP-1-agonisten en cardiovasculaire eindpunten bij obesitas zonder diabetes
JP Verlaan · Geneesmiddelenbulletin · 2025
DOI 10.35351/gebu.nl.2025.2.6
Meta-analysis
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →